With its ability to significantly reduce ApoB‐containing lipoprotein levels and a safety profile similar to placebo, obicetrapib has the potential to be a new agent in the armamentarium for dyslipidemia management and ASCVD risk reduction. Here, APOB is linked to metabolic syndrome.